Title:
MOLECULAR BIOMARKER SET FOR EARLY DETECTION OF OVARIAN CANCER
Document Type and Number:
WIPO Patent Application WO/2012/120377
Kind Code:
A3
Abstract:
Embodiments of the present invention concern methods and compositions related to detection of ovarian cancer, including detection of the stage of ovarian cancer, in some cases. In particular, the invention encompasses use of expression of TFAP2A and in some embodiments CA125 and/or E2F5 to identify ovarian cancer, including detecting mRNA and/or protein levels of the respective gene products. Kits for detection of ovarian cancer are also described.
Inventors:
BAJIC VLADIMIR (SA)
KAUR MANDEEP (SA)
KAUR MANDEEP (SA)
Application Number:
PCT/IB2012/000552
Publication Date:
June 27, 2013
Filing Date:
March 08, 2012
Export Citation:
Assignee:
UNIV KING ABDULLAH SCI & TECH (SA)
BAJIC VLADIMIR (SA)
KAUR MANDEEP (SA)
BAJIC VLADIMIR (SA)
KAUR MANDEEP (SA)
International Classes:
C12Q1/68
Domestic Patent References:
| WO2005014781A2 | 2005-02-17 |
Other References:
ANTTILA ET AL: "True", BRITISH JOURNAL OF CANCER, vol. 82, no. 12, 1 June 2000 (2000-06-01), pages 1974 - 1983, XP055029119, ISSN: 0007-0920, DOI: 10.1054/bjoc.2000.1146
KOTHANDARAMAN NARASIMHAN ET AL: "E2F5 status significantly improves malignancy diagnosis of epithelial ovarian cancer", BMC CANCER, BIOMED CENTRAL, LONDON, GB, vol. 10, no. 1, 24 February 2010 (2010-02-24), pages 64, XP021066946, ISSN: 1471-2407, DOI: 10.1186/1471-2407-10-64
KOTHANDARAMAN NARASIMHAN ET AL: "E2F5 status significantly improves malignancy diagnosis of epithelial ovarian cancer", BMC CANCER, BIOMED CENTRAL, LONDON, GB, vol. 10, no. 1, 24 February 2010 (2010-02-24), pages 64, XP021066946, ISSN: 1471-2407, DOI: 10.1186/1471-2407-10-64
Download PDF: